Day: March 31, 2026

BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita

Written by Customer Service on March 31, 2026. Posted in Mergers And Acquisitions.

LOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and health services for complex populations, today announced the completed sale of ResCare Community Living to Sevita, a leading provider of home and community-based specialty health care. The transaction reflects a shared commitment to continuity of care, operational stability, and long-term opportunity for individuals with intellectual and developmental disabilities, as well as the employees who support them every day. “The divestiture of our Community Living business was not a decision made lightly and was guided by our priority of ensuring continued high-quality, innovative care for clients,” said Jon Rousseau, President and Chief Executive...

Park Street A/S Annual General Meeting 2026

Written by Customer Service on March 31, 2026. Posted in Public Companies.

ANNUAL GENERAL MEETING OF PARK STREET A/SIn accordance with article 6.2 of the articles of association, the annual general meeting of Park Street A/S (the “Company”) is hereby called to be held on28 April 2026, at 2:00 p.m. (Danish time)The general meeting will be held at the Company’s addressAmaliegade 6, 2 tv, 1256 København KAGENDAThe board of directors has prepared the following agenda:Board of directors’ report on the Company’s activities in the past year.Presentation and approval of the audited annual report.Board of directors’ proposed resolution on the appropriation of profit or covering of loss according to the approved annual report.Presentation of and advisory vote of the remuneration report.Authorisation to acquire treasury...

Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare®

Written by Customer Service on March 31, 2026. Posted in Public Companies.

Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers’ integrated care platform NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that eligible Weight Watchers Med+ members will have access to subscription pricing for Wegovy® that significantly reduces out-of-pocket costs and is a result of expanded collaboration between Weight Watchers and Novo Nordisk. The new subscription offer gives Weight Watchers Med+ members access to the lowest available self-pay price in the market for doses of Wegovy not otherwise available through limited-time offers, saving cash-pay members...

Park Street A/S – Annual Report 2025

Written by Customer Service on March 31, 2026. Posted in Public Companies.

Park Street A/S – Annual Report 2025 Copenhagen, 31 March 2026 Park Street primarily uses EBVAT (Earnings before value adjustments and tax) as the key measure of the Group’s operating performance. The Group achieved an EBVAT of DKK 11.5 million in 2025 (2024: DKK 2.8 million), compared to previously communicated expectations of DKK 20–25 million. The variance is attributable to a combination of factors, primarily weaker than expected performance from hotel operations and the newly launched co-working site in Odense, as well as a reduced asset base following property disposal during the year. During 2025, the Group undertook several significant initiatives, including refinancing activities, operational optimisation and capex-led leasing initiatives. While some of these actions impacted short-term earnings, they are expected to deliver sustained...

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Written by Customer Service on March 31, 2026. Posted in Earnings Releases And Operating Results.

Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. Company expects to present clinical data from independent, blinded biomechanical gait analyses of the CONNECT SCI study in 2Q 2026, providing additional evidence with the potential to further support the systemic biological effect of NVG-291, differentiating genuine neural recovery from compensatory movement. Company expects to expand NVG-291 into complementary clinical indications, as informed by established preclinical efficacy, with prioritization expected to be announced by mid-2026. Successful Nasdaq listing and continued growth of leadership team supports the Company’s emergence as a leader in the development of neuroreparative therapeutics.VANCOUVER,...

Cloudastructure Inc. Reaffirms Prior Guidance of Approximately 270% Year-Over-Year Revenue Growth and More Than $5.0 Million in Recognized Revenue in 2025; Rescheduling Fiscal Year 2025 Conference Call

Written by Customer Service on March 31, 2026. Posted in Public Companies.

PALO ALTO, Ca, March 31, 2026 (GLOBE NEWSWIRE) — Cloudastructure, Inc. (Nasdaq: CSAI) (“we,” “us,” “our,” “Cloudastructure” or the “Company”) an award-winning leader in AI Surveillance and Remote Guarding, today reaffirmed its prior guidance of approximately 270% year-over-year revenue growth and more than $5.0 million in recognized revenue in 2025. Due to a scheduling conflict the Company also plans to reschedule its previously announced conference call to discuss its fiscal year 2025 financial results. Cloudastructure will announce a new date and time for the conference call as soon as practicable. ABOUT CLOUDASTRUCTURE Headquartered in Palo Alto, California, Cloudastructure’s advanced award-winning security platform utilizes a scalable cloud-based architecture that features cloud video surveillance with proprietary, state-of-the-art...

Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Written by Customer Service on March 31, 2026. Posted in Public Companies.

New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026 Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic LMs; potential to become the first FDA-approved therapy and first-line, standard-of-care treatment for serious, lifelong disease affecting an estimated more than 30,000 diagnosed patients in the U.S. Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for second half of 2026 Initiation of Phase 2 trial of QTORIN™ rapamycin for the treatment of clinically significant angiokeratomas planned for second quarter of 2026 Initiation of Phase 2 trial of QTORIN™ pitavastatin for the treatment of disseminated...

BOS Reports Financial Results for the Fourth Quarter and Full Year 2025

Written by Customer Service on March 31, 2026. Posted in Public Companies.

Delivers Record Year Performance Provides Initial 2026 Revenue and Net Income Guidance RISHON LE ZION, Israel, March 31, 2026 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (BOSC) today reported financial results for the fourth quarter and full-year ended December 31, 2025, including record revenue and profitability. Fourth Quarter 2025 Financial Highlights:Revenues$12.6M +21.5%Compared to $10.4M in Q4 2024 EBITDA$944K +32%Compared to $715K in Q4 2024Net Income$819K +68.9%Compared to $485K in Q4 2024 EPS$0.12 +50%Compared to $0.08 in Q4 2024Cash & Equivalent$11.8MAs of December 31, 2025 Contracted Backlog$24MAs of December 31, 2025Full Year 2025 Financial Highlights:Revenues$50.6M +26.6%Compared to $39.9M in 2024 EBITDA$4.6M +42.6%Compared to $3.2M in 2024Net Income$3.6M +57.0%Compared to $2.3M in 2024 EPS$0.59...

MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

Written by Customer Service on March 31, 2026. Posted in Public Companies.

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EU C-Further Consortium collaboration adds to growing non-dilutive funding for PRAME-TCR iNKT in pediatric oncology NIH STTR grant and Mary Gooze philanthropic award fully fund graft-versus-host disease (GVHD) preclinical data with clinical trial launch in 1H 2026 Keystone Symposia data report iNKT depletion in end-stage Pulmonary Fibrosis (IPF); underscores pipeline expansion Portfolio focused on high-value immune restoration with multiple 2026 clinical catalystsNEW YORK, March 31, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune...

Hypercharge Announces Appointment of Kyle Moncrief, CFA as VP, Corporate Development and FP&A, and Changes to Board of Directors

Written by Customer Service on March 31, 2026. Posted in Public Companies.

New leadership appointment supports Hypercharge’s growth pipeline, strategic partnerships, and market outreach VANCOUVER, British Columbia, March 31, 2026 (GLOBE NEWSWIRE) — Hypercharge Networks Corp. (TSXV: HC; OTC: HCNWF; FSE: PB7) (the “Company” or “Hypercharge”), a leading, smart electric vehicle (EV) charging solutions provider and network operator, is pleased to announce the appointment of Kyle Moncrief, CFA, as Vice President, Corporate Development and Financial Planning & Analysis. In this role, Mr. Moncrief will lead corporate strategy, long-term planning, and enterprise value creation initiatives, with a focus on advancing strategic partnerships, supporting revenue growth initiatives, and strengthening Hypercharge’s capital markets outreach. Working closely with the Company’s executive leadership, he will help advance...

Day: March 31, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals